Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1469-1475

  Zhao, Yu Wei ^a   Jin, Lu ^a   Li, Zhi Mian ^a   Zhao, Cheng Jian ^a   Wei, Yu Quan ^a   Yang, Han Shuo ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; MALE; MICE; MICE, INBRED BALB C; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 79960389330     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01979.x     Document Type: Article

References (38)

1. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
2. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005; 18: 485-94.
3. Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-75.
4. Millauer B, Longhi MP, Plate KH et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615-20.
5. Kou B, Li Y, Zhang L et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp Mol Pathol 2004; 76: 129-37.
6. Kunkel P, Ulbricht U, Bohlen P et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 6624-8.
7. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999; 18: 473-81.
8. Furuya M, Yonemitsu Y, Aoki I III. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des 2009; 15: 1854-67.
9. Ribatti D, Vacca A. The role of microenvironment in tumor angiogenesis. Genes Nutr 2008; 3: 29-34.
10. Brown SL, Kolozsvary A, Kim JH. Vascular targeting therapies for treatment of malignant disease. Cancer 2005; 104: 216-7.
11. Perry BN, Arbiser JL. The duality of angiogenesis: implications for therapy of human disease. J Invest Dermatol 2006; 126: 2160-6.
12. Thakker GD, Hajjar DP, Muller WA, Rosengart TK. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999; 274: 10002-7.
13. Roche S, Koegl M, Courtneidge SA. The phosphatidylinositol 3-kinase α is required for DNA synthesis induced by some, but not all, growth factors. Proc Natl Acad Sci USA 1994; 91: 9185-9.
14. Xu L, Pathak PS, Fukumura D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 2004; 10: 701-7.
15. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 2000; 60: 6201-7.
16. Zhou BP, Hu MC, Miller SA et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J Biol Chem 2000; 275: 8027-31.
17. Chang F, Lee JT, Navolanic PM et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603.
18. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615-75.
19. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439-45.
20. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97: 1749-53.
21. Schaft DWJ, Seftor REB, Seftor EA et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004; 96: 1473-7.
22. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50.
23. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71-103.
24. Ahmad S, Ahmad A, Gerasmivoskaya E, Stenmark KR, White CW. Inhibition of hypoxia-induced tolerance to subsequent hyperoxic injury in lung cells by phosphatidyl inositol 3-kinase inhibitors: LY294002 and wortmannin. Cell Mol Biol Lett 2003; 8: 570.
25. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-97.
26. Sourbier C, Lindner V, Lang H et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 2006; 66: 5130-42.
27. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-92.
28. Lee CM, Fuhrman CB, Planelles V et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 2006; 12: 250-6.
29. Gevertz JL, Torquato S. Modeling the effects of vasculature evolution on early brain tumor growth. J Theor Biol 2006; 243: 517-31.
30. Severine IG, Marketa JZ, Stephen JS et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007; 404: 15-21.
31. Kaoru H, Sachiko K, Takayo M et al. Opposite effects of wortmannin and 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride on toll-like receptor-mediated nitric oxide production: negative regulation of nuclear factor-κΒ by phosphoinositide 3-kinase. Mol Pharmacol 2006; 69: 1717-24.
32. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
33. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
34. Anke S, Dafna BS. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 11: 447-58.
35. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005; 19: 342-53.
36. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9: 267-85.
37. Folberg R, Arbieva Z, Moses J et al. Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol 2006; 169: 1376-89.
38. Maniotis AJ, Folberg R, Hess A et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-52.